Calidi Biotherapeutics financials
$1.08+0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.2M | -$4.2M | -$4.5M | -$5.0M | -$5.7M | -$5.1M | -$4.0M | -$5.2M | -$5.8M | -$6.8M | -$9.8M | -$7.2M |
| Net income | -$4.2M | -$4.4M | -$4.1M | -$10.8M | -$5.7M | -$5.0M | -$4.1M | -$5.1M | -$7.4M | -$7.2M | -$8.2M | -$2.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.94 | $-6.88 | $-6.58 | $-35.36 | $-31.75 | $-35.36 | $-28.74 | $-124.00 | $-268.00 | $-389.76 | $-279.23 | $-270.72 |
| EBITDA | -$3.7M | -$3.8M | -$4.0M | -$4.6M | -$5.3M | -$4.7M | -$4.0M | -$4.8M | -$5.1M | -$6.7M | -$9.7M | -$7.1M |
| Operating cash flow | -$4.4M | -$4.1M | -$5.0M | -$4.2M | -$4.9M | -$7.1M | -$5.4M | -$4.9M | -$5.5M | -$3.8M | -$5.2M | -$13.5M |
| Free cash flow | -$4.4M | -$4.1M | -$5.1M | -$4.3M | -$4.9M | -$7.1M | -$5.4M | -$5.0M | -$5.5M | -$3.8M | -$5.3M | -$13.6M |
| Diluted shares | 1.4M | 0.6M | 0.6M | 0.3M | 0.2M | 0.1M | 0.1M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.1M | $6.6M | $5.6M | $10.4M | $5.3M | $10.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $928.0K | $901.0K | $882.0K | $1.3M | $939.0K | $798.0K |
| Total assets | $7.2M | $9.6M | $8.9M | $14.0M | $9.4M | $15.1M |
| Total liabilities | $4.1M | $4.7M | $5.1M | $6.8M | $7.3M | $7.8M |
| Shareholders' equity | $3.1M | $4.9M | $3.8M | $7.2M | $2.1M | $7.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology